a6b176e9-f4fc-4188-9771-ab2f3e00a4a8
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 73.6646132785763
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.390
- NOTCH_SIGNALING+0.380
- APICAL_JUNCTION+0.350
- KRAS_SIGNALING_DN+0.320
- WNT_BETA_CATENIN_SIGNALING+0.320
- PANCREAS_BETA_CELLS+0.300
- COAGULATION+0.290
- IL6_JAK_STAT3_SIGNALING+0.280
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.270
- ALLOGRAFT_REJECTION+0.240
Top 10 suppressed
- E2F_TARGETS-0.530
- G2M_CHECKPOINT-0.480
- MYC_TARGETS_V1-0.460
- PROTEIN_SECRETION-0.460
- MTORC1_SIGNALING-0.420
- ANDROGEN_RESPONSE-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.340
- OXIDATIVE_PHOSPHORYLATION-0.290
- MITOTIC_SPINDLE-0.270
- PEROXISOME-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 002260fb-3015-4876-b8fd-edffd7fc95e8 | — | — | 0.902 |
| 2 | MNG1108 | — | — | 0.900 |
| 3 | R281 | — | — | 0.871 |
| 4 | TCGA-GM-A3XN-01A-12R-A22U-07 | — | A | 0.864 |
| 5 | TCGA-AC-A3W6-01A-12R-A22K-07 | — | A | 0.862 |
| 6 | fb24d93c-9681-4d45-801f-9dcfd8c5703e | — | — | 0.860 |
| 7 | SAMN03290904 | — | — | 0.860 |
| 8 | 9b308588-5e79-46ab-b186-6edd686695c6 | — | — | 0.855 |
| 9 | SRR8613743 | — | D | 0.850 |
| 10 | TCGA-LD-A74U-01A-13R-A33J-07 | — | A | 0.846 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.390 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.380 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.350 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.320 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.320 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.280 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.270 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.240 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.240 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.190 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.160 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.160 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.140 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.140 | Inavolisib | — uncovered |
| COMPLEMENT | 0.130 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.120 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |